Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 9, 2009 - Issue 6
Submit an article Journal homepage
218
Views
17
CrossRef citations to date
0
Altmetric
Reviews

Prospects of RNAi and microRNA-based therapies for hepatitis C

Qiuwei Pan Erasmus MC-University Medical Centre, Department of Gastroenterology & Hepatology, Rotterdam, The Netherlands
,
Hugo W Tilanus Erasmus MC-University Medical Centre Rotterdam, Department of Surgery, Room L458, ‘s-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands +31 10 703 2759; +31 10 703 2793; [email protected]
,
Harry LA Janssen Erasmus MC-University Medical Centre, Department of Gastroenterology & Hepatology, Rotterdam, The Netherlands
&
Luc JW van der Laan Erasmus MC-University Medical Centre Rotterdam, Department of Surgery, Room L458, ‘s-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands +31 10 703 2759; +31 10 703 2793; [email protected]
Pages 713-724 | Published online: 20 May 2009

Bibliography

  • Sarbah SA, Younossi ZM. Hepatitis C: an update on the silent epidemic. J Clin Gastroenterol 2000;30(2):125-43
  • Brown RS. Hepatitis C and liver transplantation. Nature 2005;436(7053):973-8
  • Yilmaz N, Shiffman ML, Stravitz RT, et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl 2007;13(7):975-83
  • Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358(9286):958-65
  • Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38(3):645-52
  • Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44(1):97-103
  • Samuel D, Bizollon T, Feray C, et al. Interferon-α 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003;124(3):642-50
  • Garcia-Retortillo M, Forns X. Prevention and treatment of hepatitis C virus recurrence after liver transplantation. J Hepatol 2004;41(1):2-10
  • Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347(13):975-82
  • Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36(5 Suppl 1):S237-44
  • McHutchison JG, Bartenschlager R, Patel K, Pawlotsky JM. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. J Hepatol 2006;44(2):411-21
  • Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication. Hepatology 2006;43(2 Suppl 1):S207-20
  • Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391(6669):806-11
  • Hannon GJ. RNA interference. Nature 2002;418(6894):244-51
  • Tomari Y, Zamore PD. Perspective: machines for RNAi. Genes Dev 2005;19(5):517-29
  • Jopling CL, Yi M, Lancaster AM, et al. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 2005;309(5740):1577-81
  • Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005;42(4):962-73
  • Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244(4902):359-62
  • Giannini C, Brechot C. Hepatitis C virus biology. Cell Death Differ 2003;10(Suppl 1):S27-38
  • Penin F, Brass V, Appel N, et al. Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. J Biol Chem 2004;279(39):40835-43
  • Prabhu R, Garry RF, Dash S. Small interfering RNA targeted to stem-loop II of the 5′ untranslated region effectively inhibits expression of six HCV genotypes. Virol J 2006;3:100. Published online 27 November 2006, doi: 10.1186/1743-422X-3-100
  • Kapadia SB, Brideau-Andersen A, Chisari FV. Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci USA 2003;100(4):2014-8
  • Yokota T, Sakamoto N, Enomoto N, et al. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Reports 2003;4(6):602-8
  • Wilson JA, Jayasena S, Khvorova A, et al. RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. Proc Natl Acad Sci USA 2003;100(5):2783-8
  • Randall G, Grakoui A, Rice CM. Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc Natl Acad Sci USA 2003;100(1):235-40
  • Hamazaki H, Ujino S, Abe E, et al. RNAi expression mediated inhibition of HCV replication. Nucleic Acids Symp Ser 2004;48(1):307-8
  • Ilves H, Kaspar RL, Wang Q, et al. Inhibition of hepatitis C IRES-mediated gene expression by small hairpin RNAs in human hepatocytes and mice. Ann NY Acad Sci 2006;1082:52-5
  • Kanda T, Steele R, Ray R, Ray RB. Small interfering RNA targeted to hepatitis C virus 5′ nontranslated region exerts potent antiviral effect. J Virol 2007;81(2):669-76
  • Chevalier C, Saulnier A, Benureau Y, et al. Inhibition of hepatitis C virus infection in cell culture by small interfering RNAs. Mol Ther 2007;15(8):1452-62
  • Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998;282(5386):103-7
  • Grimm D, Kay MA. Combinatorial RNAi: a winning strategy for the race against evolving targets? Mol Ther 2007;15(5):878-88
  • Wilson JA, Richardson CD. Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region. J Virol 2005;79(11):7050-8
  • Konishi M, Wu CH, Kaito M, et al. siRNA-resistance in treated HCV replicon cells is correlated with the development of specific HCV mutations. J Viral Hepat 2006;13(11):756-61
  • Lohmann V, Korner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285(5424):110-3
  • Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11(7):791-6
  • Levy S, Todd SC, Maecker HT. CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol 1998;16:89-109
  • Barth H, Schafer C, Adah MI, et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 2003;278(42):41003-12
  • Scarselli E, Ansuini H, Cerino R, et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. Embo J 2002;21(19):5017-25
  • Agnello V, Abel G, Elfahal M, et al. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999;96(22):12766-71
  • Pohlmann S, Zhang J, Baribaud F, et al. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol 2003;77(7):4070-80
  • Gardner JP, Durso RJ, Arrigale RR, et al. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc Natl Acad Sci USA 2003;100(8):4498-503
  • Evans MJ, von Hahn T, Tscherne DM, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007;446(7137):801-5
  • Zheng A, Yuan F, Li Y, et al. Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus. J Virol 2007;81(22):12465-71
  • Meertens L, Bertaux C, Cukierman L, et al. The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus. J Virol 2008;82(7):3555-60
  • Lanford RE, Evans MJ, Lohmann V, et al. The accelerating pace of HCV research: a summary of the 15th International Symposium on Hepatitis C Virus And Related Viruses. Gastroenterology 2009;136(1):9-16
  • Ploss A, Evans MJ, Gaysinskaya VA, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009;457(7231):882-6
  • Wang C, Gale M Jr, Keller BC, et al. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol Cell 2005;18(4):425-34
  • Evans MJ, Rice CM, Goff SP. Genetic interactions between hepatitis C virus replicons. J Virol 2004;78(21):12085-9
  • Hamamoto I, Nishimura Y, Okamoto T, et al. Human VAP-B is involved in hepatitis C virus replication through interaction with NS5A and NS5B. J Virol 2005;79(21):13473-82
  • Watashi K, Ishii N, Hijikata M, et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005;19(1):111-22
  • Okamoto T, Nishimura Y, Ichimura T, et al. Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. EMBO J 2006;25(20):5015-25
  • Randall G, Panis M, Cooper JD, et al. Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci USA 2007;104(31):12884-9
  • Ng TI, Mo H, Pilot-Matias T, et al. Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology. Hepatology 2007;45(6):1413-21
  • Supekova L, Supek F, Lee J, et al. Identification of human kinases involved in hepatitis C virus replication by small interference RNA library screening. J Biol Chem 2008;283(1):29-36
  • McKeating JA, Zhang LQ, Logvinoff C, et al. Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J Virol 2004;78(16):8496-505
  • Henry SD, Metselaar HJ, Lonsdale RC, et al. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-α. Gastroenterology 2006;131(5):1452-62
  • Meuleman P, Hesselgesser J, Paulson M, et al. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 2008;48(6):1761-8
  • Lavillette D, Morice Y, Germanidis G, et al. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 2005;79(10):6023-34
  • Zhu Q, Oei Y, Mendel DB, et al. Novel robust hepatitis C virus mouse efficacy model. Antimicrob Agents Chemother 2006;50(10):3260-8
  • Wu GY, Konishi M, Walton CM, et al. A novel immunocompetent rat model of HCV infection and hepatitis. Gastroenterology 2005;128(5):1416-23
  • Meuleman P, Leroux-Roels G. The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV. Antiviral Res 2008;80(3):231-8
  • McCaffrey AP, Meuse L, Pham T-TT, et al. RNA interference in adult mice. Nature 2002;418:38-9
  • Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411(6836):494-8
  • Sledz CA, Holko M, de Veer MJ, et al. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003;5(9):834-9
  • Persengiev SP, Zhu X, Green MR. Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA 2004;10(1):12-8
  • Robbins MA, Rossi JJ. Sensing the danger in RNA. Nat Med 2005;11(3):250-1
  • Kleinman ME, Yamada K, Takeda A, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008;452(7187):591-7
  • Corey DR. Chemical modification: the key to clinical application of RNA interference? J Clin Invest 2007;117(12):3615-22
  • Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005;23(8):1002-7
  • Morrissey DV, Blanchard K, Shaw L, et al. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 2005;41(6):1349-56
  • Hu YB, Li DG, Lu HM. Modified synthetic siRNA targeting tissue inhibitor of metalloproteinase-2 inhibits hepatic fibrogenesis in rats. J Gene Med 2007;9(3):217-29
  • Watanabe T, Umehara T, Yasui F, et al. Liver target delivery of small interfering RNA to the HCV gene by lactosylated cationic liposome. J Hepatol 2007;47(6):744-50
  • Song E, Zhu P, Lee SK, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005;23(6):709-17
  • Wen WH, Liu JY, Qin WJ, et al. Targeted inhibition of HBV gene expression by single-chain antibody mediated small interfering RNA delivery. Hepatology 2007;46(1):84-94
  • Sato Y, Murase K, Kato J, et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol 2008;26(4):431-42
  • Kim SI, Shin D, Lee H, et al. Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes. J Hepatol 2009;50(3):479-88
  • Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009;457(7228):426-33
  • Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev 2009;8(2):129-38
  • Uprichard SL, Boyd B, Althage A, Chisari FV. Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc Natl Acad Sci USA 2005;102(3):773-8
  • Sakamoto N, Tanabe Y, Yokota T, et al. Inhibition of hepatitis C virus infection and expression in vitro and in vivo by recombinant adenovirus expressing short hairpin RNA. J Gastroenterol Hepatol 2008;23(9):1437-47
  • Schulick AH, Vassalli G, Dunn PF, et al. Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. J Clin Invest 1997;99(2):209-19
  • Crowther C, Ely A, Hornby J, et al. Efficient inhibition of hepatitis B virus replication in vivo using polyethylene glycol-modified adenovirus vectors. Hum Gene Ther 2008;19(11):1325-32
  • Lu S, Cullen BR. Adenovirus VA1 noncoding RNA can inhibit small interfering RNA and microRNA biogenesis. J Virol 2004;78(23):12868-76
  • Andersson MG, Haasnoot PC, Xu N, et al. Suppression of RNA interference by adenovirus virus-associated RNA. J Virol 2005;79(15):9556-65
  • Kochanek S, Clemens PR, Mitani K, et al. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase. Proc Natl Acad Sci USA 1996;93(12):5731-6
  • Ruiz R, Witting SR, Saxena R, Morral N. Robust hepatic gene silencing for functional studies using helper-dependent adenovirus vectors. Hum Gene Ther 2009;20(1):87-94
  • Witting SR, Brown M, Saxena R, et al. Helper-dependent adenovirus-mediated short hairpin RNA expression in the liver activates the interferon response. J Biol Chem 2008;283(4):2120-8
  • Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006;12(3):342-7
  • Gao L, Aizaki H, He JW, Lai MM. Interactions between viral nonstructural proteins and host protein hVAP-33 mediate the formation of hepatitis C virus RNA replication complex on lipid raft. J Virol 2004;78(7):3480-8
  • Nakai H, Fuess S, Storm TA, et al. Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol 2005;79(1):214-24
  • Wang Z, Ma HI, Li J, et al. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther 2003;10(26):2105-11
  • Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996;272(5259):263-7
  • Henry SD, van der Wegen P, Metselaar HJ, et al. Simultaneous targeting of HCV replication and viral binding with a single lentiviral vector containing multiple RNA interference expression cassettes. Mol Ther 2006;14(4):485-93
  • Takigawa Y, Nagano-Fujii M, Deng L, et al. Suppression of hepatitis C virus replicon by RNA interference directed against the NS3 and NS5B regions of the viral genome. Microbiol Immunol 2004;48(8):591-8
  • Johnston JC, Gasmi M, Lim LE, et al. Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. J Virol 1999;73(6):4991-5000
  • Poeschla EM, Wong-Staal F, Looney DJ. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med 1998;4(3):354-7
  • Rizvi TA, Panganiban AT. Simian immunodeficiency virus RNA is efficiently encapsidated by human immunodeficiency virus type 1 particles. J Virol 1993;67(5):2681-8
  • Markusic DM, Kanitz A, Oude-Elferink RP, Seppen J. Preferential gene transfer of lentiviral vectors to liver-derived cells, using a hepatitis B peptide displayed on GP64. Hum Gene Ther 2007;18(7):673-9
  • Chang K, Elledge SJ, Hannon GJ. Lessons from nature: microRNA-based shRNA libraries. Nat Methods 2006;3(9):707-14
  • Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006;441(7092):537-41
  • Giering JC, Grimm D, Storm TA, Kay MA. Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther 2008;16(9):1630-6
  • Shaked A, Csete ME, Drazan KE, et al. Adenovirus-mediated gene transfer in the transplant setting. II. Successful expression of transferred cDNA in syngeneic liver grafts. Transplantation 1994;57(10):1508-11
  • Olthoff KM, Judge TA, Gelman AE, et al. Adenovirus-mediated gene transfer into cold-preserved liver allografts: survival pattern and unresponsiveness following transduction with CTLA4Ig. Nat Med 1998;4(2):194-200
  • Gong N, Dong C, Chen Z, et al. Adenovirus-mediated antisense-ERK2 gene therapy attenuates chronic allograft nephropathy. Transplant Proc 2006;38(10):3228-30
  • Dudler J, Simeoni E, Fleury S, et al. Gene transfer of interleukin-18-binding protein attenuates cardiac allograft rejection. Transpl Int 2007;20(5):460-6
  • Henry SD, van der Wegen P, Metselaar HJ, et al. Hydroxyethyl starch-based preservation solutions enhance gene therapy vector delivery under hypothermic conditions. Liver Transpl 2008;14(12):1708-17
  • Gottwein E, Cullen BR. Viral and cellular microRNAs as determinants of viral pathogenesis and immunity. Cell Host Microbe 2008;3(6):375-87
  • Jopling CL, Schutz S, Sarnow P. Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe 2008;4(1):77-85
  • Liu J. Control of protein synthesis and mRNA degradation by microRNAs. Curr Opin Cell Biol 2008;20(2):214-21
  • Shan Y, Zheng J, Lambrecht RW, Bonkovsky HL. Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gastroenterology 2007;133(4):1166-74
  • Zhu Z, Wilson AT, Mathahs MM, et al. Heme oxygenase-1 suppresses hepatitis C virus replication and increases resistance of hepatocytes to oxidant injury. Hepatology 2008;48(5):1430-9
  • Henke JI, Goergen D, Zheng J, et al. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J 2008;27(24):3300-10
  • Pedersen IM, Cheng G, Wieland S, et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007;449(7164):919-22
  • Sarasin-Filipowicz M, Krol J, Markiewicz I, et al. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med 2009;15(1):31-3
  • Murakami Y, Aly HH, Tajima A, et al. Regulation of the hepatitis C virus genome replication by miR-199a*. J Hepatol 2009;50(3):453-60
  • Hutvagner G, Simard MJ, Mello CC, Zamore PD. Sequence-specific inhibition of small RNA function. PLoS Biol 2004;2(4):E98. Published online 24 February, 2004, doi: 10.1371/journal.pbio.0020098
  • Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with ‘lantagomirs’. Nature 2005;438(7068):685-9
  • Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006;3(2):87-98
  • Valoczi A, Hornyik C, Varga N, et al. Sensitive and specific detection of microRNAs by northern blot analysis using LNA-modified oligonucleotide probes. Nucleic Acids Res 2004;32(22):e175. Published online 16 November 2004, doi: 10.1093/nar/gnh171
  • Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008;452(7189):896-9
  • Elmen J, Lindow M, Silahtaroglu A, et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 2008;36(4):1153-62
  • Fabani MM, Gait MJ. miR-122 targeting with LNA/2′-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. RNA 2008;14(2):336-46
  • Bhat B, Esau C, Davis S, et al. 2′-O-Methoxyethyl/2′-Fluoro modified oligonucleotides result in more potent inhibition of micro RNA-122 in vivo: a target implicatedin HCV replication. Nucleic Acids Symp Ser 2008;(52):69
  • Kronke J, Kittler R, Buchholz F, et al. Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs. J Virol 2004;78(7):3436-46
  • De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005;436(7053):953-60
  • Watanabe T, Sudoh M, Miyagishi M, et al. Intracellular-diced dsRNA has enhanced efficacy for silencing HCV RNA and overcomes variation in the viral genotype. Gene Ther 2006;13(11):883-92
  • Kruger M, Beger C, Welch PJ, et al. Involvement of proteasome α-subunit PSMA7 in hepatitis C virus internal ribosome entry site-mediated translation. Mol Cell Biol 2001;21(24):8357-64
  • Spangberg K, Wiklund L, Schwartz S. HuR, a protein implicated in oncogene and growth factor mRNA decay, binds to the 3′ ends of hepatitis C virus RNA of both polarities. Virology 2000;274(2):378-90
  • Korf M, Jarczak D, Beger C, et al. Inhibition of hepatitis C virus translation and subgenomic replication by siRNAs directed against highly conserved HCV sequence and cellular HCV cofactors. J Hepatol 2005;43(2):225-34
  • Chung KH, Hart CC, Al-Bassam S, et al. Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155. Nucleic Acids Res 2006;34(7):e53
  • Liu YP, Haasnoot J, ter Brake O, et al. Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res 2008;36(9):2811-24
  • Pan Q, Henry SD, Metselaar HJ, et al. Combined antiviral activity of interferon-alpha and RNA interference directed against hepatitis C without affecting vector delivery and gene silencing. J Mol Med. 2009; Apr 30. [Epub ahead of print]
  • Randall G, Chen L, Panis M, et al. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology 2006;131(5):1584-91
  • Waterhouse PM, Wang MB, Lough T. Gene silencing as an adaptive defence against viruses. Nature 2001;411(6839):834-42
  • Voinnet O. RNA silencing as a plant immune system against viruses. Trends Genet 2001;17(8):449-59
  • Wilkins C, Dishongh R, Moore SC, et al. RNA interference is an antiviral defence mechanism in Caenorhabditis elegans. Nature 2005;436(7053):1044-7
  • Wang XH, Aliyari R, Li WX, et al. RNA interference directs innate immunity against viruses in adult Drosophila. Science 2006;312(5772):452-4
  • Segers GC, Zhang X, Deng F, et al. Evidence that RNA silencing functions as an antiviral defense mechanism in fungi. Proc Natl Acad Sci USA 2007;104(31):12902-6
  • Cullen BR. Is RNA interference involved in intrinsic antiviral immunity in mammals? Nat Immunol 2006;7(6):563-7
  • de Vries W, Berkhout B. RNAi suppressors encoded by pathogenic human viruses. Int J Biochem Cell Biol 2008;40(10):2007-12
  • Wang Y, Kato N, Jazag A, et al. Hepatitis C virus core protein is a potent inhibitor of RNA silencing-based antiviral response. Gastroenterology 2006;130(3):883-92
  • Ji J, Glaser A, Wernli M, et al. Suppression of short interfering RNA-mediated gene silencing by the structural proteins of hepatitis C virus. J Gen Virol 2008;89(Pt 11):2761-6
  • Chen W, Zhang Z, Chen J, et al. HCV core protein interacts with Dicer to antagonize RNA silencing. Virus Res 2008;133(2):250-8

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.